자궁경부암 근접치료 시 선량 검증 프로그램을 통한 임상적 위험성 평가
Clinical Risk Evaluation Using Dose Verification Program of Brachytherapy for Cervical Cancer
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
The purpose of this study is to evaluate the clinical risk according to the applicator heterogeneity, mislocation, and tissue heterogeneity correction through a dose verification program during brachytherapy of cervical cancer. We performed image processing with MATLAB on images acquired with CT simulator. The source was modeled and stochiometric calibration and Monte-Carlo algorithm were applied based on dwell time and location to calculate the dose, and the secondary cancer risk was evaluated in the dose verification program. The result calculated by correcting for applicator and tissue heterogeneity showed a maximum dose of about 25% higher. In the bladder, the difference in excess absolute risk according to the heterogeneity correction was not significant. In the rectum, the difference in excess absolute risk was lower than that calculated by correcting applicator and tissue heterogeneity compared to the water-based calculation. In the femur, the water-based calculation result was the lowest, and the result calculated by correcting the applicator and tissue heterogeneity was 10% higher. A maximum of 14% dose difference occurred when the applicator mislocation was 20 mm in the Z-axis. In a future study, it is expected that a system that can independently verify the treatment plan can be developed by automating the interface between the treatment planning system and the dose verification program.
Abstract
The purpose of this study is to evaluate the clinical risk according to the applicator heterogeneity, mislocation, and tissue heterogeneity correction through a dose verification program during brachytherapy of cervical cancer. We performed image processing with MATLAB on images acquired with CT simulator. The source was modeled and stochiometric calibration and Monte-Carlo algorithm were applied based on dwell time and location to calculate the dose, and the secondary cancer risk was evaluated in the dose verification program. The result calculated by correcting for applicator and tissue heterogeneity showed a maximum dose of about 25% higher. In the bladder, the difference in excess absolute risk according to the heterogeneity correction was not significant. In the rectum, the difference in excess absolute risk was lower than that calculated by correcting applicator and tissue heterogeneity compared to the water-based calculation. In the femur, the water-based calculation result was the lowest, and the result calculated by correcting the applicator and tissue heterogeneity was 10% higher. A maximum of 14% dose difference occurred when the applicator mislocation was 20 mm in the Z-axis. In a future study, it is expected that a system that can independently verify the treatment plan can be developed by automating the interface between the treatment planning system and the dose verification program.
참고문헌 (43)
- Cancer Incidence in Korea 2017, "Ministry of Health & Welfare", ~ (2020)
- Onal C, "Uterine perforation during 3-dimensional image-guided brachytherapy in patients with cervical cancer : Baskent University experience", Int J Gynecol Cancer, 24(2), pp.346~351 (2014)
- Atahan IL, "Long-term outcome and prognostic factors in patients with cervical carcinoma : A retrospective study", Int J Gynecol Cancer, 17(4), pp.833~842 (2007)
- Eifel PJ, "Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix : A patterns of care study", Int J Radiat Oncol Biol Phys, 60(4), pp.1144~1153 (2004)
- Lee HJ, "Long-term outcomes of concomitant chemoradiotherapy incorporating high-dose-rate brachytherapy to treat locally advanced cervical cancer", Tumori, 98(5), pp.615~621 (2012)
- Crook JM, "Dose-volume analysis and the prevention of radiation sequelae in cervical cancer", Radiother Oncol, 8(4), pp.321~332 (1987)
- Banerjee R, "Brachytherapy in the treatment of cervical cancer : A review", Int J Womens Health, 6, pp.555~564 (2014)
- Vojtisek R, "Late side effects of 3T MRI-guided 3D high-dose rate brachytherapy of cervical cancer : Institutional experiences", Strahlenther Onkol, 195(11), pp.972~981 (2019)
- Chen J, "Analysis of Applicator Insertion Related Acute Side Effects for Cervical Cancer Treated With Brachytherapy", Front Oncol, 11, pp.677052~ (2021)
- Isohashi F, "Dose rate in the highest irradiation area of the rectum correlates with late rectal complications in patients treated with high-dose-rate computed tomography-based image-guided brachytherapy for cervical cancer", J Radiat Res, 62(3), pp.494~501 (2021)
- Segedin B, "Uterine perforation-5-year experience in 3-D image guided gynaecological brachytherapy at Institute of Oncology Ljubljana", Radiol Oncol, 47(2), pp.154~160 (2013)
- Irvin W, "Uterine perforation at the time of brachytherapy for carcinoma of the cervix", Gynecol Oncol, 90(1), pp.113~122 (2003)
- Kim DW, "Risk of second cancer from scattered radiation of intensity-modulated radiotherapies with lung cancer", Radiat Oncol, 8, pp.47~ (2013)
- National Research Council, "Health risks from exposure to low levels of ionizing radiation: BEIR VII Phase 2" (2006), National Academies Press
- Lee B, "Radiotherapy-induced secondary cancer risk for breast cancer : 3D conformal therapy versus IMRT versus VMAT", J Radiol Prot, 34(2), pp.325~331 (2014)
- Lee B, "Secondary cancer-incidence risk estimates for external radiotherapy and high-dose-rate brachytherapy in cervical cancer : Phantom study", J Appl Clin Med Phys, 17(5), pp.124~132 (2016)
- Barnes EA, "Prospective comparison of clinical and computed tomography assessment in detecting uterine perforation with intracavitary brachytherapy for carcinoma of the cervix", Int J Gynecol Cancer, 17(4), pp.821~826 (2007)
- Nag S, "Proposed guidelines for image-based intracavitary brachytherapy for cervical carcinoma : Report from Image-Guided Brachytherapy Working Group", Int J Radiat Oncol Biol Phys, 60(4), pp.1160~1172 (2004)
- Rivard MJ, "Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations", Med. Phys, 31(3), pp.633~672 (2004)
- Daskalov GM, "Analytical approach to heterogeneity correction factor calculation for brachytherapy", Med Phys, 25(5), pp.722~735 (1998)
- Anagnostopoulos G, "An analytical dosimetry model as a step towards accounting for inhomogeneities and bounded geometries in 192Ir brachytherapy treatment planning", Phys Med Biol, 48(11), pp.1625~1647 (2003)
- Poon E, "A CT-based analytical dose calculation method for HDR 192Ir brachytherapy", Med Phys, 36(9), pp.3982~3994 (2009)
- Tedgren AK, "Accounting for high Z shields in brachytherapy using collapsed cone superposition for scatter dose calculation", Med Phys, 30(8), pp.2206~2217 (2003)
- Ravikumar B, "Determination of the tissue inhomogeneity correction in high dose rate Brachytherapy for Iridium-192 source", J Med Phys, 37(1), pp.27~31 (2012)
- Mikell JK, "Impact of heterogeneity-based dose calculation using a deterministic grid-based Boltzmann equation solver for intracavitary brachytherapy", Int J Radiat Oncol Biol Phys, 83(3), pp.e417~e422 (2012)
- Hyer DE, "The dosimetric impact of heterogeneity corrections in high-dose-rate 192Ir brachytherapy for cervical cancer : Investigation of both conventional Point-A and volume-optimized plans", Brachytherapy, 11(6), pp.515~520 (2012)
- Wu CH, "HDR Brachytherapy Dose Distribution is Influenced by the Metal Material of the Applicator", Sci Rep, 5, pp.17863~ (2015)
- Okamoto H, "Independent assessment of source position for gynecological applicator in high-dose-rate brachytherapy", J Contemp Brachytherapy, 9(5), pp.477~486 (2017)
- Zhang SX, "Quantifying tumor-selective radiation dose enhancements using gold nanoparticles : A monte carlo simulation study", Biomed Microdevices, 11(4), pp.925~933 (2009)
- 조성구, "Monte Carlo Simulation Study on Dose Enhancement by Gold Nanoparticles in Brachytherapy", Journal of the Korean Physical Society, 56(6), pp.1754~1758 (2010), 한국물리학회
- Schneider W, "Correlation between CT numbers and tissue parameters needed for Monte Carlo simulations of clinical dose distributions", Phys Med Biol, 45(2), pp.459~478 (2000)
- Kang DJ, "Development of clinical application program for radiotherapy induced cancer risk calculation using Monte Carlo engine in volumetric-modulated arc therapy", Radiat Oncol, 16(1), pp.108~ (2021)
- Watzke O, "A pragmatic approach to metal artifact reduction in CT : Merging of metal artifact reduced images", Eur Radiol, 14(5), pp.849~856 (2004)
- Filippi AR, "Intensity Modulated Radiation Therapy and Second Cancer Risk in Adults", Int J Radiat Oncol Biol Phys, 100(1), pp.17~20 (2018)
- Schneider U, "Radiation risk estimates after radiotherapy : Application of the organ equivalent dose concept to plateau dose-response relationships", Radiat Environ Biophys, 44(3), pp.235~239 (2005)
- Donovan EM, "Second cancer incidence risk estimates using BEIR VII models for standard and complex external beam radiotherapy for early breast cancer", Med Phys, 39(10), pp.5814~5824 (2012)
- Schneider U, "Estimation of radiation-induced cancer from three-dimensional dose distributions : Concept of organ equivalent dose", Int J Radiat Oncol Biol Phys, 61(5), pp.1510~1515 (2005)
- Tian Z, "Monte Carlo dose calculations for high-dose-rate brachytherapy using GPU-accelerated processing", Brachytherapy, 15(3), pp.387~398 (2016)
- Ferrari P, "MCNPX internal dosimetry studies based on the NORMAN-05 voxel model", Radiat Prot Dosimetry, 127(1-4), pp.209~213 (2007)
- Taylor RE, "Benchmarking brachydose : Voxel based EGSnrc Monte Carlo calculations of TG-43 dosimetry parameters", Med Phys, 34(2), pp.445~457 (2007)
- 장경환, "토모테라피에서 통계적공정관리를 이용한 EBT 필름 기반의 선량품질보증의 치료계획 가이드라인", 방사선기술과학, 45(5), pp.439~448 (2022), 대한방사선과학회
- 강동진, "비 인두암 체적 조절 호형 방사선 치료의 선량 계산 격자 크기에 따른 선량 체적 지수와 방사선 생물학적 지수의 평가", 방사선기술과학, 43(4), pp.265~272 (2020), 대한방사선과학회